Andrew Therrien, PhD
이사 (Engagement Manager)
Expertise:
Andy is an Engagement Manager at EVERSANA MANAGEMENT CONSULTING with a background in chemistry, chemical engineering and life sciences consulting.
Prior to joining EVERSANA, Andy was a consultant at EQUITAS Life Sciences, where he helped to design and execute full product launch management, including pricing, go-to-market strategy and commercial launch training. Additionally, Andy has applied his educational expertise to support commercial excellence, learning engagement and training curriculum design in the pharmaceutical industry.
Andy’s laboratory research experience as a doctoral student in chemistry at Tufts University and chemical engineering as a post-doctoral scholar at UC–Santa Barbara has resulted in 24 peer-reviewed publications. His scientific research was focused on the fields of catalysis, nanotechnology and plasmonics. Andy’s academic achievements demonstrate his passion for learning, comfort with ambiguity and solution-oriented mindset.
Articles by Andrew Therrien, PhD
Price Right or Pay Later
Dive into the intricate world of pharmaceutical pricing with “Price Right or Pay Later” by Christopher Nüesch, Chad McAuliffe, and Andrew Therrien. In this groundbreaking paper, EVERSANA exposes the critical yet often overlooked nuances of pricing strategies in the pharmaceutical industry. Through meticulous analysis and real-world examples, discover why setting the right price at launch […]
Critical Success Factors for Launching Products with Orphan Drug Designation
The Orphan Drug Act (ODA) was passed in 1983 to financially incentivize pharmaceutical companies to develop drugs for rare diseases or conditions, defined as a disease or condition that affects less than 200,000 people in the US.1 The financial incentives offered by the ODA are substantial and include tax credits up to 50% of the […]
Breaking through Barriers: Critical Success Factors for Launching Products with Breakthrough Therapy Designation
The FDA’s Breakthrough Therapy Designation (BTD) expedites patient access to innovative new treatments. While speeding up these processes can get new drugs to patients in need faster than they normally would through standard tracks, limited clinical evidence at launch and a compressed launch timeline can present stumbling blocks and uncertainties for commercialization teams tackling launch […]